The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.

Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

At present relates to a glucopyranosyl derivative and application thereof. In particular, relates to a glucopyranosyl derivative as a sodium-dependent glucose transporters1 (SGLT1) inhibitor, and a pharmaceutically acceptable salt or a stereoisomer thereof, and further relates to a pharmaceutical composition containing the derivative. Further relating to uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases

At present relates to a glucopyranosyl derivative and application thereof. In particular, relates to a glucopyranosyl derivative as a sodium-dependent glucose transporters1 (SGLT1) inhibitor, and a pharmaceutically acceptable salt or a stereoisomer thereof, and further relates to a pharmaceutical composition containing the derivative. Further relating to uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases

A composition for mitigating, treating, and/or preventing symptoms associated with veisalgia. In one embodiment the composition comprises one or more ingredients selected from the group consisting of: dihydromyricetin, N-acetyl cysteine, salicin, quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, monk fruit, turmeric, curcumin, ginger root, and black pepper extract. A method for treating symptoms associated with veisalgia is also described. In one embodiment, the composition is administered in liquid or pill form.

A composition for mitigating, treating, and/or preventing symptoms associated with veisalgia. In one embodiment the composition comprises one or more ingredients selected from the group consisting of: dihydromyricetin, N-acetyl cysteine, salicin, quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, monk fruit, turmeric, curcumin, ginger root, and black pepper extract. A method for treating symptoms associated with veisalgia is also described. In one embodiment, the composition is administered in liquid or pill form.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

The present invention provides a novel use of a compound having a plasminogen activator inhibitor-1 (PAI-1) inhibitory effect. Specifically, a compound having a PAI-1 inhibitory effect is used as an intranostimulator, an immune checkpoint inhibitor, an inhibitor for exacerbation of tumor cells caused by PD-L1, or an enhancer of immunotherapy for tumors, based on the inhibitory effect of the compound on expression induction of immune checkpoint molecules.